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Abstract Sildenafil is a highly effective oral agent for the
treatment of erectile dysfunction of multiple etiologies.
Although in clinical practice sildenafil is often used in de-
pressed patients, its influence on the pathophysiology of de-
pression remains unclear. The aim of the present study was to
evaluate the antidepressant-like activity following acute and
subchronic treatment with sildenafil in naïve mice as well as in
mice with reserpine- and restraint stress-induced depressive-
like behavior. Since corticosterone is released in response to
acute stress, we also aimed to assess the influence of sildenafil
on serum corticosterone level in non-stressed and stressed
animals. The antidepressant activity of sildenafil was assessed
in the forced swim test. Corticosterone serum level was deter-
mined by using ELISAmethod, while brain and serum silden-
afil level via HPLC method. Sildenafil administered acutely
exerted an antidepressant-like effect. Subchronic (14 days)
administration of sildenafil resulted only in a weak
antidepressant-like effect when evaluated 24 h after the last
dose. Acute but not subchronic sildenafil administration re-
versed the reserpine- and stress-induced immobility in the
forced swim test. The lack of effects of sildenafil after sub-
chronic treatment could have been related to its complete
elimination from the brain within 24 h from the last injection.
Interestingly, acute administration of sildenafil produced a
marked increase in serum corticosterone level in both non-
stressed and stressed animals. Sildenafil exerts differential ef-
fects in the forced swim test after acute and subchronic ad-
ministration. Further studies on the antidepressant activity of
sildenafil are required.
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Abbreviations
cGMP cyclic guanosine 3´,5´-monophosphate
i.p. intraperitoneally
IS internal standard
LPS lipopolysaccharide
NO nitric oxide
PDE5 phosphodiesterase type 5
SEM standard error of the mean
Introduction
Depression and erectile dysfunction are both highly prevalent
disorders that exhibit a marked comorbidity. The causal rela-
tionship between them is complex and multifactorial since the
occurrence of either disorder may be a symptom or a cause of
the other. Moreover, erectile dysfunction is a common adverse
effect of antidepressant medication (Nurnberg et al. 2002).
Sildenafil citrate, commonly known as Viagra®, is the first-
line oral treatment for erectile dysfunction with well-proven
efficacy in depressed patients, including those in whom erec-
tile dysfunction developed secondary to antidepressant drug
therapy (Nurnberg and Hensley 2003; Seidman et al. 2001). It
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acts as a selective phosphodiesterase type 5 (PDE5) inhibitor.
Following activation of the nitric oxide (NO)/guanosine 3´,5´-
monophosphate (cGMP) signaling pathway during sexual
arousal, inhibition of PDE5 activity by sildenafil leads to the
increase in the intracellular level of cGMP and improves
smooth muscles relaxation in the corpus cavernosum (Rosen
and McKenna 2002).
Although sildenafil was designed as a drug that works
mainly in peripheral tissues, it is capable of crossing the blood
brain barrier and affecting central PDE5 activity. Numerous
findings showed that sildenafil exerts various beneficial ef-
fects in the central nervous system such as stimulation of
neurogenesis, memory enhancement, attenuation of the learn-
ing impairment and neuroprotection. Not surprisingly,
targeting PDE5 with sildenafil has emerged as a new thera-
peutic strategy in the treatment of many neurological and neu-
ropsychiatric conditions (Uthayathas et al. 2007).
Clinical studies showed that sildenafil is a highly effective
oral agent for the treatment of erectile dysfunction in de-
pressed patients (Nurnberg et al. 2002; Nurnberg and
Hensley 2003). However, its influence on the symptoms of
depression has not been extensively studied in clinics so far.
Seidman et al. (2001) reported a marked improvement in de-
pressive symptoms in depressedmenwith erectile dysfunction
treated with sildenafil, but the observed effect was rather due
to a significant improvement in the erectile function and a
subsequent improvement in quality of life than due to direct
mood-enhancing properties of sildenafil. Data obtained in
animal studies are contradictory. Several studies showed that
sildenafil (at doses ranging up to 20mg/kg) given acutely does
not affect behavioral response of mice challenged with the
forced swim test (Almeida et al. 2006; Brocardo et al. 2008;
Ghasemi et al. 2008; Savegnago et al. 2008; Socała et al.
2012c). Even though sildenafil given acutely alone had no
effect on immobility time in the forced swim test, it was re-
ported to reverse the antidepressant action of many com-
pounds including adenosine (Kaster et al. 2005), memantine
(Almeida et al. 2006), diphenyl diselenide (Savegnago et al.
2008), lithium (Ghasemi et al. 2008), escitalopram
(Zomkowski et al. 2010), paroxetine (Socała et al. 2012d) or
magnesium (Socała et al. 2012a). By contrast, sildenafil aug-
mented the anti-immobility action of some other antidepres-
sant drugs such as amitriptyline (Socała et al. 2012c),
mianserin and tianeptine (Socała et al. 2012b).
Brink and co-workers (2008) observed that repeated (7 days)
administration of sildenafil (10 mg/kg) did not change immo-
bility time in the forced swim test in rats. Interestingly, in the
same study sildenafil exerted antidepressant-like effect after
central muscarinic receptors blockage with atropine, which
suggests that it may possess antidepressant properties that are
attenuated because of its simultaneous cholinotropic action.
This observation was further supported by the study, in which
we demonstrated that the anti-immobility action of sildenafil
(1.25–5 mg/kg) in mice can be revealed even after single ad-
ministration with joint injection of antimuscarinic agent – sco-
polamine (Socała et al. 2012c).
It has been subsequently shown that sildenafil possesses
acute antidepressant-like effect in the forced swim test at
higher doses of 30 and 60mg/kg. Sub-acute treatment (3 days)
with sildenafil at 20 mg/kg also reduced the duration of im-
mobility (Matsushita et al. 2012). Furthermore, a low dose of
sildenafil 5 mg/kg was effective against lipopolysaccharide
(LPS)-induced depressive-like behavior in mice. This study
proved the involvement of the NO/cGMP/PDE5 pathway in
the behavioral alterations triggered by LPS injection in mice
(Tomaz et al. 2014). It is widely known that inflammation
underlies depressive disorder and the anti-inflammatory prop-
erties of sildenafil (Raposo et al. 2013; Karakoyun et al. 2011)
could have contributed to its antidepressant effect in
LPS-treated mice. In another study, Wang et al. (2014)
demonstrated that sildenafil given chronically at a dose
of 30 mg/kg reversed the depressive-like behavior in the
forced swim test as well as in the tail suspension test in mice
subjected to the chronic unpredictable mild stress procedure.
The observed effect was mediated via the cAMP response
element-binding protein (CREB)/brain-derived neurotrophic
factor (BDNF)/neuropeptide VGF signaling pathway.
With this background, the present study was undertaken to
evaluate the effect of an acute and subchronic treatment with
sildenafil in the forced swim test in (a) naïve mice, (b) mice
pretreated with reserpine, and (c) mice subjected to acute re-
straint stress. Reserpine non-selectively depletes brain mono-
amines and thereby produces a depressive-like behavior in
rodents, while acute restraint stress is an unavoidable stress
exposure that also causes behavioral despair in animals. Since
corticosterone is released in response to stress situation, we
aimed also to evaluate the influence of acute and repeated
sildenafil treatment on serum corticosterone level in non-
stressed and stressed animals. In addition, brain and serum
concentrations of sildenafil after acute and subchronic treat-
ment were determined.
Materials and methods
Animals
Naïve male Albino Swiss mice weighing 25–30 g were used
in the study. The animals were obtained from a licensed breed-
er (Laboratory Animals Breeding, Słaboszów, Poland) and
housed under strictly controlled laboratory conditions (tem-
perature maintained at 22–23 °C, relative humidity
45–55 %) with an artificial 12-h light/dark cycle (light on at
6:00 a.m.). A nutritionally-balanced rodent chow diet
(Agropol S.J., Motycz, Poland) and tap water were continu-
ously available. Before being used in the experiments, mice
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were allowed an adaptation period of at least 7 days. All ex-
periments were performed between 8:00 a.m. and 14:00 p.m.
to minimize circadian influences, after a minimum 30-min
acclimatization to the experimental room. The animals were
randomly assigned to the experimental groups. Each animal
was used only once.
The study was carried out under experimental protocols
approved by the Ethical Committee of the Medical
University in Lublin. All procedures were in strict compliance
with the European Union Directive of 22 September 2010
(2010/63/EU) and Polish legislation concerning animal exper-
imentation. All efforts were made to minimize animal suffer-
ing as well as the number of animals used in the study.
Treatments
Sildenafil citrate (kindly provided by Polpharma S.A.,
Starogard Gdański, Poland) was suspended in a 1 % solution
of Tween 80 (POCH, Gliwice, Poland) in normal saline and
administered acutely 30 min before the test or repeatedly ev-
ery 24 h for 14 consecutive days. In the subchronic studies, all
experiments were performed 24 h after the last injection in
order to avoid acute effects of the drug on animal behavior
(Dadomo et al. 2013).
Reserpine was dissolved in a 1 % solution of dimethyl sulf-
oxide (DMSO, ICN Biomedicals, Inc., Aurora, OH, USA) in
normal saline and injected 240 min before challenging animals
to the behavioral tests. The procedure of reserpine-induced be-
havioral despair in mice was conducted according to the
method described by Dhir and Kulkarni (2007).
All solutions and suspensions were prepared freshly and
administered intraperitoneally (i.p.) in a constant volume of
0.1 ml per 10 g body weight. Control animals received an i.p.
injection of a respective vehicle or combination of vehicles.
Acute restraint stress procedure
Acute restraint stress procedure was performed according to
the modified method described by Poleszak et al. (2006).
Mice were placed individually in air-assessable Plexiglas cyl-
inders (28 mm diameter, 100 mm long) for 180 min. The
animals were not physically compressed during restraint pro-
cedure and did not experience pain. They could rotate from a
supine to prone position. Immediately after restraint, the ani-
mals were moved back to the home cages and challenged to
the behavioral tests or decapitation procedure 30 min after
immobilization. The non-stressed control animals were left
undisturbed in their home cages.
Forced swim test
The forced swim procedure was carried out according to the
slightly modified method of Porsolt et al. (1977). Mice were
placed individually into glass cylinders (height 25 cm, diam-
eter 10 cm) containing 11 cm of water maintained at temper-
ature 23–25 °C. Animals were allowed to swim for 6 min.
After the initial 2 min of vigorous activity, the total duration
of immobility was recorded during the last 4 min of the test.
Mice were considered immobile when they stopped strug-
gling, remained floating passively, made no attempts to escape
and showed only slow limb movements necessary to keep its
head above the water. Water in the beakers was regularly
changed between subjects. The immobility time was recorded
by a trained observer with the help of cumulative stopwatches.
Data obtained in groups of 10–12 mice were expressed as
means (in s) ± the standard error of the mean (SEM).
Locomotor activity test
Spontaneous locomotor activity of mice was measured with
the usage of the IR Actimeter system (Panlab/Harvard
Apparatus, Barcelona, Spain). The apparatus consisted of a
square arena surrounded by a 25 × 25 cm frame containing a
total of 16 × 16 infrared beams located on the sides. The frame
was coupled to a computerized control unit. Mice were placed
individually in the actimeter, in which they were allowed to
explore freely for 6 min. The arena was cleaned thoroughly
with a 0.1 % acetic acid solution before each mouse was
placed in it. Occlusions of the photo beams were recorded
automatically and analyzed with a computerized system
(SedaCom32, Panlab/Harvard Apparatus, Barcelona, Spain).
Locomotor activity was defined as a horizontal activity with
displacement and was expressed in terms of total number of
interruptions of the photo beams measured during the last
4 min of the test, which corresponds with the time interval
analyzed in the forced swim test. Data obtained in groups of
9–12 animals were expressed as means of activity counts/
4 min ± SEM.
Sildenafil determination
Sildenafil was administered at the highest dose used in behav-
ioral studies, i.e., 60 mg/kg. In acute studies, sildenafil was
injected 30 min before the decapitation. In subchronic studies,
sildenafil was injected for 14 consecutive days and the decap-
itation was performed 24 h after the last injection.
Concentrations of sildenafil in murine serum and brain tis-
sue were determined according to the method described else-
where (Strach et al. 2015) with slight modifications. Prior to
the analysis, brains were homogenized in distilled water (1:4,
w/v) with a tissue homogenizer TH220 (Omni International,
Inc., Warrenton, VA, USA). Plasma (50 or 200 μl for acute or
subchronic dosing, respectively) or brain homogenate (100 μl
or 1 ml) were spiked with 10 μl of 10 μg/ml paroxetine (IS)
and vortexed (Reax top, Heidolph, Germany) for 30 s. The
samples were alkalized with 50 μl of 4 M sodium hydroxide
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solution, mixed briefly on the vortex mixer and extracted with
1 ml of ethyl acetate:hexane (30:70, v/v) mixture for 20 min
on a shaker (VXRVibrax, IKA, Germany). After centrifuga-
tion (EBA 12 R, Hettich, Germany) at 3000 rpm for 15 min,
the organic layers were transferred into new Eppendorf tubes
containing 100 μl of a methanol and 0.1 M sulfuric acid mix-
ture (10:90, v/v). Then the samples were shaken and centri-
fuged again. Finally, 50 μl of each acidic layer were injected
into the HPLC system.
The HPLC system (Thermo Separation Products, San Jose,
CA, USA) consisted of a P100 pump fitted with a Rheodyne
7125 manual injector (Cotati, CA, USA) with a 50 μl sample
loop, a UV100 variable length UV/VIS detector operating at
230 nm, and an SP4400 integrator (ChromJet). The chromato-
graphic analysis was carried out at 21 °C on the Supelcosil™
PCN column 250x4.6 mm (Sigma-Aldrich, USA) with 5 μm
particles, protected with the SUPELCOSIL™ LC-PCN guard
column (Sigma-Aldrich, USA) with the same packing material.
Themobile phase consisted of acetonitrile and 50mMpotassium
dihydrogen phosphate buffer (pH 4.5) mixed in 25:75 (v/v) ratio.
The flow rate of 1ml/minwas used throughout the analytical run.
The retention times of sildenafil and IS were approximately
7.35 and 9.15 min. The calibration curve constructed by plot-
ting the ratio of the peak area of sildenafil to IS versus concen-
tration of sildenafil was linear in the tested concentration ranges
and the limit of quantification was 10 ng/ml (or g tissue). No
interfering peaks were observed in the chromatograms. The
assay was reproducible with low intra- and inter-day variation
(coefficient of variation less than 10 %). The extraction effi-
ciencies of sildenafil and IS were higher than 80 %. Sildenafil
concentrations were expressed in μg/ml of serum or μg/g of
wet brain tissue.
Corticosterone determination
In order to determine the influence of sildenafil on serum corti-
costerone level, the animals were divided into the following
groups: (a) non-stressed control animals, (b) stressed control
animals, (c) non-stressed sildenafil-treated animals and (d)
stressed sildenafil-treated animals. Sildenafil was administered
at the highest dose used in behavioral studies, i.e., 60 mg/kg.
Sildenafil or vehicle were injected acutely, 30 min before the
decapitation. In subchronic studies, sildenafil or vehicle were
injected for 14 consecutive days and the decapitation was per-
formed 24 h after the last injection. The trunk blood was col-
lected into polyethylene tubes. Serum was isolated 1 h after
blood coagulation by centrifugation at 5000 × g for 10 min at
4 °C and frozen at −20 °C. Serum corticosterone level was
measured using a commercially available enzyme-linked immu-
noassay (ELISA) kit (Enzo Life Sciences, Inc., USA; Cat No
ADI-900-097) according to the manufacturer’s protocol. Serum
corticosterone level was expressed in ng/ml. The minimum de-
tectable concentration of corticosterone was 27.0 pg/ml.
Statistical analysis
Statistical analysis was performed by using one-way analysis
of variance (one-way ANOVA) followed by Tukey post hoc
test for multiple comparisons. Changes in serum corticoste-
rone level were analyzed by using a two-way ANOVA follow-
ed by Bonferroni post hoc test. The factors of variation were
sildenafil treatment and acute restraint stress exposure.
Differences were considered statistically significant when p
values were equal to or less than 0.05. All calculations were
carried out with GraphPad Prism version 5.03 for Windows
(GraphPad Software, San Diego, CA, USA).
Results
Effect of acute and subchronic sildenafil treatment
in the forced swim test in naïve mice
The effects of acute and subchronic treatments with sildenafil
on immobility time in naïve mice is shown in Fig. 1A–C (one
wayANOVA: F(2,33) = 12.47, p < 0.0001 for acute treatment;
F(3,43) = 1.197, p = 0.322 and F(2,33) = 3.532, p = 0.041 for
subchronic treatment, respectively). The first experiment was
conducted in order to evaluate the acute antidepressant-like
effect of high doses (30 and 60 mg/kg) of sildenafil. The
obtained results showed that sildenafil at the highest dose
tested, i.e., 60 mg/kg, significantly decreased immobility time
as compared to the control group (p < 0.001). Repeated ad-
ministration of sildenafil in a range of doses 5–30 mg/kg did
not significantly alter the total immobility duration in the
forced swim test in naïve mice. The highest dose tested, i.e.,
60 mg/kg, caused only weak anti-immobility effect (p < 0.05
vs. the control group).
There were no signs of toxicity or otherwise abnormal be-
havior following high-dose sildenafil in both treatment
regimens.
Effect of acute and subchronic sildenafil treatment
in the forced swim test in reserpine-treated mice
The effects of acute and subchronic administration of silden-
afil on immobility time in reserpine-treated mice are shown in
Fig. 2A–B (one way ANOVA: F(4,54) = 11.58, p < 0.0001 for
acute treatment and F(4,54) = 11.64, p < 0.0001 for subchron-
ic treatment, respectively). Reserpine (2 mg/kg) produced be-
havioral despair in mice, which was shown by an increase in
the total immobility duration in the forced swim test
(p < 0.001 vs. control groups in both acute and subchronic
studies). Sildenafil injected acutely at doses of 40 and 60 mg/
kg reversed the reserpine-induced behavioral despair in mice
and caused a significant decrease in the immobility duration as
compared to the reserpine-treated group (p < 0.001 for both
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studied groups). However, no such effect was observed when
sildenafil, at doses of 20, 40, and 60 mg/kg, was administered
repeatedly.
Effect of acute and subchronic sildenafil treatment
in the forced swim test in restraint-stressed mice
The effects of acute and subchronic administration of silden-
afil on immobility time in mice subjected to the acute restraint
stress are shown in Fig. 3A–B (one way ANOVA: F(4,
53) = 13.28, p < 0.0001 for acute treatment and F(4,
52) = 10.98, p < 0.0001 for subchronic treatment, respective-
ly). Acute restraint stress induced a significant increase in
immobility time in the forced swim test in both acute
and subchronic studies (p < 0.01 and p < 0.001 vs.
vehicle-treated non-stressed control mice, respectively).
After acute administration, sildenafil at a dose of
20 mg/kg did not produce any significant changes in
immobility time as compared to vehicle-treated stressed
and non-stressed animals. However, when injected at a
dose of 40 mg/kg, sildenafil normalized the increased
immobility time in animals subjected to the acute re-
straint stress (p < 0.001 vs. stressed control mice).
Sildenafil at the highest dose of 60 mg/kg caused fur-
ther decrease in immobility time as compared to both
vehicle-treated stressed- and non-stressed animals
(p < 0.001 and p < 0.05, respectively). Repeated admin-
istration of sildenafil did not affect significantly immo-
bility time as compared to control mice subjected to the
acute restraint stress.
Fig. 1 Effect of acute (panel A) and subchronic (panel B and C)
treatment with sildenafil in the forced swim test in mice. In acute
studies, sildenafil was administered i.p. 30 min before the test. In
subchronic studies, sildenafil was administered once daily for 14
consecutive days. Control animals received 1 % Tween 80. Each
experimental group consisted of 11–12 animals. Data are presented as
means + SEM. * p < 0.05, *** p < 0.001 as compared to the control
group (one-way ANOVA followed by Tukey post hoc test)
Fig. 2 Effect of acute (panel A) and subchronic (panel B) treatment with
sildenafil in the forced swim test in reserpine-treated mice. In acute
studies, sildenafil was administered i.p. 30 min before the test. In
subchronic studies, sildenafil was administered once daily for 14
consecutive days. Reserpine was injected i.p. 240 min before the test.
Control animals received 1 % Tween 80 + 1 % DMSO. Each
experimental group consisted of 11–12 animals. Data are presented as
means + SEM. ** p < 0.01, *** p < 0.001 as compared to the control
group; ### p < 0.001 as compared to the reserpine-treated group (one-way
ANOVA followed by Tukey post hoc test)
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Effect of treatments on spontaneous locomotor activity
in mice
As shown in Table 1, no significant changes in locomotor
activity were observed following either acute or subchronic
administration of sildenafil at doses of 30 and 60 mg/kg (one
way ANOVA: F(2,27) = 1.52, p = 0.237 for acute treatment
and F(2,32) = 1.04, p = 0.366 for subchronic treatment,
respectively).
Reserpine injected alone produced a marked decrease in
locomotor activity (p < 0.0001 vs. control groups in both acute
and subchronic studies). Co-administration of sildenafil at a
dose of 60 mg/kg did not cause any additional changes as
compared to the reserpine-treated group (one way ANOVA:
F(2,31) = 106.2, p < 0.0001 for acute treatment and F(2,
33) = 44.85, p < 0.0001 for subchronic treatment,
respectively).
In acute studies, acute restraint stress caused significant
decrease in activity counts in the vehicle-treated group (one
way ANOVA: F(2,31) = 8.886, p = 0.0009). Sildenafil
injected at a dose of 60 mg/kg did not cause any additional
changes in locomotor activity (p < 0.01 vs. the control group).
In subchronic studies, no significant changes in locomotor
activity were observed (one way ANOVA: F(2,33) = 1.197,
p = 0.315).
Brain and serum concentrations of sildenafil
Total brain and serum concentrations of sildenafil after acute
and repeated administration (at a dose of 60 mg/kg) are shown
in Table 2. Concentrations of this drug in serum and brain
tissue measured 30 min following drug administration were
comparable and relatively high. This indicates that sildenafil is
rapidly and effectively distributed to its site of action. In turn,
24 h after discontinuation of the 14-day subchronic treatment
with this drug it was not detectable in brain tissue. In serum,
sildenafil was still present 24 h after the termination of the
repeated dosing, probably as a result of a slow return of the
drug from peripheral tissues to the bloodstream.
Corticosterone concentrations
The influence of acute sildenafil treatment on serum cortico-
sterone level in non-stressed and stressed animals is shown in
Fig. 4A. A two-way ANOVA revealed a significant effect of
acute restraint stress (F(1,37) = 9.40, p = 0.004), a significant
effect of treatment (F(1,37) = 275.06, p < 0.0001) and no
interaction between acute restraint stress and sildenafil treat-
ment (F(1,37) = 0.15, p = 0.698). Although acute restraint
stress increased corticosterone concentration in control ani-
mals, a Bonferroni post hoc test did not show a statistically
significant effect. Acute administration of sildenafil in non-
stressed animals caused a marked increase in corticosterone
level (p < 0.001 vs. the non-stressed control group). In mice
subjected to the acute restraint stress, sildenafil caused a fur-
ther increase in corticosterone concentration (p < 0.001 vs. the
non-stressed control group and the stressed control group).
The influence of repeated sildenafil treatment on
serum corticosterone level in non-stressed and stressed
animals is shown in Fig. 4B. A two-way ANOVA revealed
a significant effect of acute restraint stress (F(1,37) = 32.70,
p < 0.0001) , no s ign i f ican t e ffec t o f t rea tment
(F(1,37) = 0.02, p = 0.878) and no interaction between acute
restraint stress and sildenafil treatment (F(1,37) = 0.14,
p = 0.714). A Bonferroni post hoc test showed a statistically
significant increase in corticosterone level in control mice
subjected to the acute restraint stress as well as in stressed
mice injected subchronically with sildenafil (p < 0.001 vs.
the non-stressed control group).
Discussion
Targeting PDE5 with sildenafil has recently gained attention
of some researchers as a new therapeutic approach in the
Fig. 3 Effect of acute (panel A) and subchronic (panel B) treatment with
sildenafil in the forced swim test in mice subjected to the acute restraint
stress. In acute studies, sildenafil was administered i.p. 30 min before the
test. In subchronic studies, sildenafil was administered once daily for 14
consecutive days. Control animals received 1 % Tween 80 + 1 %DMSO.
Each experimental group consisted of 10–12 animals. Data are presented
as means + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 as compared to
the control group; ### p < 0.001 as compared to the stressed control group
(one-way ANOVA followed by Tukey post hoc test)
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treatment of depression (Matsushita et al. 2012; Tomaz
et al. 2014; Wang et al. 2014). The antidepressant-like
effect of sildenafil has been assessed almost exclusively
in the forced swim test in rodents that remains one of
the most widely used tools for screening antidepres-
sants. As the influence of sildenafil on depressive-like
behavior in this test is ambiguous, we aimed to provide
more data on the effect of sildenafil administered acute-
ly and subchronically in the forced swim test in mice.
In the first series of experiments, the antidepressant-like
efficacy of sildenafil injected alone in naïve mice was
evaluated. In our former study, acute administration of
sildenafil at doses of 5–20 mg/kg did not affect animal
behavior in the forced swim test in mice (Socała et al.
2012c). In the present study, we showed that sildenafil
produced an antidepressant-like effect at a relatively high
dose of 60 mg/kg. We expected that repeated treatment would
potentiate the antidepressant-like effect of sildenafil.
However, after subchronic administration, sildenafil showed
poor anti-immobility action, only at the highest dose of 60mg/
kg. In the next series of experiments, the effect of acute and
subchronic treatment with sildenafil was investigated in mice
with depressive-like behavior induced by reserpine pretreat-
ment or acute restraint stress. Both reserpine and acute immo-
bilization prolonged the duration of immobility in mice.
Sildenafil given at doses of 40 and 60 mg/kg reversed the
behavioral despair in reserpine-treated as well as in stressed
mice. By contrast, subchronic treatment with sildenafil did not
produce any significant effects.
The main findings of the present study indicated differen-
tial effects of acute and subchronic treatment with sildenafil in
the forced swim test in mice. Sildenafi l exerted
antidepressant-like effects only after acute treatment with high
doses that are 3–5 times higher than the equivalent recom-
mended dose for humans (50 mg) and this observation is
consistent with findings of Matsushita and co-workers
(2012). The lack of antidepressant-like activity after subchron-
ic treatment is rather unexpected as sildenafil has been
Table 1 Effect of different
treatments on spontaneous
locomotor activity in mice
Treatment Activity counts/4 min n p value
acute 1 % Tween 80 1209.0 ± 92.6 10
sildenafil 30 mg/kg 974.9 ± 107.0 11 0.237
sildenafil 60 mg/kg 972.7 ± 132.0 9
subchronic 1 % Tween 80 1191.0 ± 46.6 11
sildenafil 30 mg/kg 1283.0 ± 66.2 12 0.366
sildenafil 60 mg/kg 1324.0 ± 77.4 12
acute 1 % Tween 80 + 1 % DMSO 1083.0 ± 101.5 10
1 % Tween 80 + reserpine (2 mg/kg) 77.1 ± 21.1 12 < 0.001
sildenafil 60 mg/kg + reserpine (2 mg/kg) 65.67 ± 22.7 12 < 0.001
subchronic 1 % Tween 80 + 1 % DMSO 1192.0 ± 94.9 12
1 % Tween 80 + reserpine (2 mg/kg) 220.8 ± 73.5 12 < 0.001
sildenafil 60 mg/kg + reserpine (2 mg/kg) 360.1 ± 63.6 12 < 0.001
acute 1 % Tween 80 1134.0 ± 88.6 12
1 % Tween 80 + restraint stress 786.3 ± 64.0 11 < 0.01
sildenafil 60 mg/kg + restraint stress 708.4 ± 73.7 11 < 0.01
subchronic 1 % Tween 80 963 ± 64.9 12
1 % Tween 80 + restraint stress 968.3 ± 94.7 12 0.315
sildenafil 60 mg/kg + restraint stress 1126 ± 91.5 12
Data are presented as means ± SEM. In acute studies, sildenafil was injected 30 min before the test. In subchronic
studies, sildenafil was administered once daily for 14 consecutive days and the locomotor activity test was
performed 24 h after the last injection. Data were analyzed with one-way ANOVA followed by Tukey post hoc
test
Table 2 Brain and serum
concentrations of sildenafil
following different dosing modes
Treatment Brain concentration (μg/g) Serum concentration (μg/ml) n
acute sildenafil 60 mg/kg 9.72 ± 1.07 10.98 ± 0.94 12
subchronic sildenafil 60 mg/kg not detectable 0.04 ± 0.01 12
Data are presented as means ± SEM. In acute treatment, sildenafil was administered at a dose of 60mg/kg, 30min
before decapitation. In chronic treatment, sildenafil was injected for 14 days at a dose of 60 mg/kg and decapi-
tation was performed 24 h after the last injection
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already reported to have antidepressant-like effect after chron-
ic treatment in mice (Wang et al. 2014). A possible explana-
tion for the discrepancy between our results and results
obtained byWang et al. (2014) is a different scheme of chronic
treatments. Wang et al. (2014) reported the antidepressant-like
effect of sildenafil (30 mg/kg) injected repeatedly for 21 days
with the last injection made 60min before the forced swim test
in mice. In our study, sildenafil was administered for 14 con-
secutive days and the animals were subjected to the swim
session 24 h after the last administration. There was no addi-
tional injection on the day of the forced swim test. This treat-
ment schedule was chosen in order to avoid any acute effects
of sildenafil treatment and it was based on the observation
made by Dadomo and co-workers (2013). In their study, sil-
denafil was given every other day for 35 days and all behav-
ioral tests were performed in the day without an injection. The
obtained results showed that sildenafil administered in this
manner increased competitive aggression, environmental and
social exploration and reduced anxiety-like behaviors
(Dadomo et al. 2013). It seems that after chronic exposure to
sildenafil, some behavioral effects should be anticipated ~24 h
after the last injection and there was no definite need for the
additional injection on the day of the behavioral tests. This
manner of administration helps to distinguish between acute
and chronic effects of the tested compound. Noteworthy, the
anti-immobility effects of antidepressant compounds injected
chronically with 24-h break between the last injection and
swim session were reported (Doboszewska et al. 2015; Guo
and Lu 2014; Nowak et al. 2003).
Several explanations can be proposed to account for the
differential effects of acute and repeated sildenafil treatment.
Firstly, the lack of antidepressant-like effect after subchronic
treatment could have been a result of the activation of negative
feedback mechanism within the NO/cGMP/PDE5 signaling
pathway. Prolonged inhibition of PDE5 by repeated sildenafil
administration leads to the accumulation of cGMP. A high
concentration of cGMP could have caused a negative feed-
back on NO synthase with subsequent reduction of NO level
(Hotchkiss et al. 2005; Kyratsas et al. 2013). Nitric oxide
plays a prominent role in the pathogenesis of depression be-
cause it modulates the release of many neurotransmitters such
as serotonin, noradrenaline, dopamine and glutamate (Dhir
and Kulkarni 2011). Thus, different changes in NO concen-
tration after acute and repeated sildenafil treatment might have
been accountable for different behavioral response in the
forced swim test. Of note, differential effects of acute and
chronic sildenafil treatment on serotonin and dopamine turn-
over have already been reported (Kyratsas et al. 2013).
Secondly, a possible withdrawal effect following repeated
sildenafil administration should be considered. Although the
issue of addiction to sildenafil was not extensively studied,
epidemiological studies show that sildenafil is sometimes
abused in a recreational fashion. Sildenafil was also reported
to exert rewarding properties in the conditioned place prefer-
ence paradigm inmice (Tahsili-Fahadan et al. 2006).Moreover,
sildenafil-treated mice were more aggressive one week follow-
ing cessation of 4 weeks of treatment (Hotchkiss et al. 2005).
Increased immobility time in the forced swim test is one of the
behavioral symptoms of withdrawal in rodents. In the present
study, the lack of the anti-immobility action after subchronic
treatment could have been one of the behavioral effects associ-
ated with discontinuation of the treatment. Nevertheless, this is
only a speculation and possible addictive effects of sildenafil
use should be carefully evaluated in further studies.
Although the forced swim test is the most commonly used
animal model for assessing both depressive- and
antidepressant-like activity, a range of factors influence the be-
havior in the forced swim test and complicates the comparison
across different studies. These factors include strain of mice,
age, gender, individual differences between animals, housing,
pretreatment schedule, laboratory conditions, depth of water or
exposure to the pre-test swim session (Bogdanova et al. 2013;
Petit-Demouliere et al. 2005). Some of these factors could have
also contributed to the difference between our results and the
results obtained by other groups. For instance, we scored ani-
mals only for the last 4 min of the 6-min swim session and no
Fig. 4 Effect of acute (panel A) or subchronic (panel B) treatment with
sildenafil and acute restraint stress on serum corticosterone concentrations
in mice. In acute studies, sildenafil was administered i.p. 30 min before
the test. In subchronic studies, sildenafil was administered once daily for
14 consecutive days. Control animals received 1 % Tween 80 + 1 %
DMSO. Each experimental group consisted of 9–11 animals. ***
p < 0.001 as compared to the non-stressed control group; ### p < 0.001
as compared to the control stressed group (two-way ANOVA followed by
Bonferroni post hoc test)
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pre-test session was employed in the present study, as it is not
recommended for mice (Gardier and Bourin 2001; Petit-
Demouliere et al. 2005). In contrast, Matsushita et al. (2012),
who reported the antidepressant-like effect of sildenafil after a
sub-chronic treatment, scored the immobility time for the last
3 min of the 6-min swim session after the pre-test swim session.
Total brain and serum concentrations of sildenafil after acute
and repeated treatment were determined in order to check
whether repeated administration of sildenafil might result in
accumulation of this compound in the organism. Interestingly,
sildenafil was not detectable in the brain tissue 24 h after the
termination of a 14-days continuous sildenafil treatment. In
serum, sildenafil was still measurable after discontinuation of
the treatment but at much lower concentrations than those after
an acute administration. These results suggest that the lack of
anti-immobility action of sildenafil after subchronic treatment
was related to the fact that the drug was eliminated from brain
within 24 h following the last injection. In clinical practice,
antidepressants have a delayed onset of action and chronic
treatment is required. Interestingly, in the forced swim test the
effectiveness of acute treatment with antidepressant agents is a
well-known phenomenon and chronic treatment usually in-
crease the antidepressant potential of the tested compounds
(Petit-Demouliere et al. 2005). It is presumed that repeated
treatment with antidepressant drugs leads to long-term adaptive
changes, which account for the antidepressant effect. These
changes include receptor desensitization, alteration in cell sig-
naling and synaptic plasticity, stimulation of neurogenesis, or
changes in gene expression (Millan 2006). Therefore, there is a
need for more studies assessing the above-mentioned adaptive
changes after chronic exposure to sildenafil.
It is widely known that there is a close relationship between
stress, the hypothalamic–pituitary–adrenocortical (HPA) axis
and depression. The HPA axis is activated upon exposure to
stress situation, which triggers the release of cortisol (in
humans) or corticosterone (in mice) from the adrenal cortex
(Sturm et al. 2015). In the present study, we also aimed to
evaluate the influence of sildenafil on corticosterone release in
non-stressed and stressedmice. In studies assessing acute effects
of sildenafil, acute restraint stress caused a ~ 3-fold increase in
serum corticosterone level. Unexpectedly, sildenafil administra-
tion produced a ~ 9.5- and 11.5-fold increase in serum cortico-
sterone in non-stressed and stressed animals, respectively. To
the best of our knowledge, there is no data on the impact of
sildenafil on corticosterone release. Inhibition of PDE5 and sub-
sequent accumulation of cGMP may affect the HPA axis at all
levels and increase the secretion of corticosterone. The mecha-
nism underlying the ability of sildenafil to increase corticoste-
rone secretion remains to be determined. Of note, there is one
study, in which cGMP injected directly into the hypothalamus
caused a marked increase in serum corticosterone level in rats
(Endroczi 1980). In studies assessing the effect of sildenafil
injected repeatedly, sildenafil did not cause any changes in
corticosterone concentrations. This could be explained by the
dramatic changes in sildenafil concentrations in serum and brain
within 24 h after the termination of the subchronic treatment.
Compounds that increase general locomotor activity can pro-
vide false positive results in the forced swim test. Since sildenafil
did not affect locomotor activity in the present study, its effects in
the forced swim test were not related to alterations in locomotion.
In summary, the present findings demonstrate that sildena-
fil, at a relatively high dose, exerts better antidepressant-like
activity in the forced swim test after acute than repeated treat-
ment. Moreover, acute but not subchronic treatment with sil-
denafil reversed the reserpine- and stress-induced behavioral
despair in mice. The obtained results did not confirm previous
suggestions (Matsushita et al. 2012; Socała et al. 2012c;
Tomaz et al. 2014; Wang et al. 2014) that sildenafil would
be an effective therapy for depression, especially given the
concern raised by the acute effect of sildenafil on corticoste-
rone release.
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